Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma.

Download

Drug Category : Array

Conference Category : Array

Lead Author : Lunning M, O'Brien S, et al.

Published Date : 09/12/2014

Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2020/05/Lunning-ASH-2014-Oral-U2-UTX-TGR-FINAL.pdf

Download Text : Download

Popup Confirmation? :

site-sidebar-layout : default

ast-site-content-layout : default

site-content-style : default

site-sidebar-style : default

theme-transparent-header-meta : default

stick-header-meta : default

astra-migrate-meta-layouts : set